CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

On August 3, 2020 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, reported that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Monday, August 10, and will host a corporate update conference call at 4:30pm Eastern Time (Press release, CorMedix, AUG 3, 2020, View Source [SID1234569342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Monday, August 10th @ 4:30pm ET

Domestic: 877-423-9813

International: 201-698-8573

Conference ID: 13707638

Webcast: Webcast Link

Immodulon and Champalimaud Foundation announce collaboration to investigate IMM-101 in difficult to treat cancers

On August 3, 2020 Immodulon, the immuno-oncology company, and the Champalimaud Foundation, a private, non-profit, research organisation in Lisbon, Portugal, reported research intended to examine the potential use of IMM-101, in combination with other treatments, to achieve clinically favourable, anti-tumour directed cellular immune responses in advanced cancers including, but not limited to, pancreatic cancer, glioblastoma and sarcoma (Press release, Immodulon Therapeutics, AUG 3, 2020, View Source [SID1234565507]). The first studies are expected to commence in the second half of 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Jaap Kampinga, Chief Executive Officer of Immodulon, commented:
"We are thrilled to announce our collaboration with the Champalimaud Foundation. There is a clear unmet medical need for effective treatments against these devastating cancers. Despite the advent of immune checkpoint inhibitors, pancreatic cancer and sarcomas remain exceedingly challenging to treat, and novel combination treatments will be required to make progress in these cancers. The Champalimaud Foundation, as a centre of excellence, is well suited to researching such treatment regimens and to carry out these clinical studies. We are proud that the Champalimaud Foundation has selected IMM-101 as a backbone immunotherapy to develop novel personalised treatments, and we look forward to working further with this fantastic organisation."

Dr. Markus Maeurer, heading the Immunotherapy/Immunosurgery programme, noted:
"I am glad to be working together with the excellent Immodulon team. The quality and quantity of cellular immune responses in the biological therapy of cancer is key to achieving clinically relevant immune responses. Anti-cancer directed immune responses may exist in patients with cancer, yet they may become ineffective: they need to be ‘re-wired’. Newly elicited immune responses that specifically target cancer cells also need to have a certain quality and to be able to enter into the tumour tissue in order to be effective. Immodulon’s IMM-101 may help to bring us closer to achieve these goals based on available preclinical and clinical IMM-101 data and aid to design safe and
effective therapies for patients with cancer, particularly for patients with ‘difficult-to-treat-cancers’, such as pancreatic cancer. We hope – by implementing IMM-101 in our strategies – to be able to elicit ‘smarter’ immune responses that are more effective in eradicating cancer cells and in establishing long-term, protective immune memory."

‘Re-wiring’ immune responses – Personalised therapies for patients with cancer aim to direct immune cells against mutations, changes in the DNA, that are exclusively present in cancer cells, but not in healthy cells. If immune cells can be sufficiently activated and ‘trained’ to recognise these mutations, they may eliminate cancer cells without harming healthy tissue. These mutations, alterations in the genetic code, may be different for each individual patient.

Activation of immune cells needs an ‘alarm’ signal that activates and stimulates them to multiply. IMM-101 may help to provide this signal. However, this may not be sufficient in order to achieve a
relevant clinical effect: immune cells recognising cancer cells need to have a certain quality and produce molecules that are able to fight off and ultimately eradicate cancer cells. Nevertheless, this often is not possible for immune cells from patients with cancer: they have a reduced ‘fitness’, they are exhausted and are not able to eliminate cancer cells effectively.

IMM-101 may help to change this non-productive behaviour of the immune system, it may aid to ‘un-learn’ non-effective response patterns and correct immune exhaustion. Therefore, we hope that IMM-101 helps to correct several immune mechanisms that failed in patients with cancer and leads to activation of immune cells that target specifically cancer cells, correct immune exhaustion and increase ‘fitness’ in immune cells in order to fight against cancer more effectively.

Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

On August 3, 2020 Aileron Therapeutics (NASDAQ:ALRN) reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month (Press release, Aileron Therapeutics, AUG 3, 2020, View Source [SID1234565068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, August 6, 2020
Event: William Blair Biotech Focus Conference 2020
Time: 12:00 pm ET
*Fireside chat

Thursday, August 13, 2020
Event: Canaccord Genuity 40th Annual Growth Conference
Time: 4:30 pm ET
*Company overview and business update presentation

Live webcasts of these events will be available under the Investors and Media section of Aileron’s website at View Source A replay of the webcasts will be archived on Aileron’s website for 30 days following the respective events.

Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

On August 3, 2020 Aileron Therapeutics (NASDAQ:ALRN) reported that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-label Phase 1b clinical study of ALRN-6924 (Press release, Aileron Therapeutics, AUG 3, 2020, View Source [SID1234565067]). Aileron is focused on transforming the experience of chemotherapy for cancer patients by developing and delivering a novel chemoprotective medicine to protect against multiple chemotherapy-induced side effects. The proof-of-concept Phase 1b study is evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced bone marrow toxicities, such as severe anemia, thrombocytopenia and neutropenia, in patients with p53-mutated small cell lung cancer (SCLC) who are being treated with topotecan. The protocol for this study consists of a phase 1b and a randomized, controlled phase 2; the Phase 1b has two parts: dose optimization and schedule optimization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re very encouraged by the data we reported from the dose optimization part of the Phase 1b in June demonstrating ALRN-6924’s potential to shield multiple healthy cell types from chemotherapy-induced damage without limiting the effect of chemotherapy on cancer cells," said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. "Per the interim findings, the 0.3 mg/kg dose of ALRN-6924 achieved the most robust and consistent chemoprotective effects of the three dose levels evaluated. The chemoprotection results were further supported by pharmacodynamic biomarker results also observed in the interim analysis."

Dr. Aivado continued, "We look forward to reporting the final results of the dose optimization part of the Phase 1b, including findings from the 0.3 mg/kg expansion cohort, as well as preliminary results from the recently initiated schedule optimization part of the Phase 1b, in Q4 of this year. We believe that the results from the Phase 1b, along with results from a healthy volunteer study that we plan to initiate in Q3 of this year, will further support and de-risk our plans to develop ALRN-6924 as a chemoprotective agent for patients with multiple cancer types who are treated with various chemotherapies."

In June 2020, Aileron announced positive interim data from the dose optimization part of the Phase 1b study demonstrating that treatment with ALRN-6924 resulted in protective effects against severe chemotherapy-induced anemia and thrombocytopenia in patients across three dose levels (0.3, 0.6, and 1.2 mg/kg) relative to historical controls. In addition, patients treated with 0.3 mg/kg ALRN-6924 also met the protocol-defined criterion for reduction of NCI CTC Grade 3/4 neutropenia to ≤50% in the first treatment cycle, triggering a cohort expansion at this dose level, from six to 14 patients.

As previously guided, in the fourth quarter of 2020, Aileron plans to report final Phase 1b dose optimization data, including data from the dose optimization expansion cohort as well as pharmacodynamic biomarker and tumor efficacy data, in addition to preliminary Phase 1b schedule optimization data. Additionally, in the third quarter or 2020, Aileron plans to initiate enrollment in a healthy volunteer study to determine dosing schedules for ALRN-6924 that will support and further de-risk the company’s long-term vision to provide a chemoprotective medicine for patients with a p53-mutation regardless of cancer type or chemotherapeutic drug. Aileron will continue to carefully monitor the effect of the coronavirus pandemic on its clinical trial sites and the healthcare system, which may impact its planned data announcements.

About the Dose Optimization Expansion Cohort Design

In the dose optimization expansion cohort, which has completed planned enrollment of eight patients, ALRN-6924 is being administered at a 0.3 mg/kg dose level 24 hours before each dose of topotecan. Topotecan is being administered days 1 through 5 every 21 days.

How ALRN-6924 Works to Protect Healthy Cells from Chemotherapy-Induced Damage

ALRN-6924 is being developed by Aileron as a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53-mutations to reduce or eliminate chemotherapy-induced side effects.

Chemotherapy targets cells that are cycling, or undergoing the process of cell division. In cancer cells, the cell cycle is unchecked, which leads to uncontrolled cell proliferation, a hallmark of cancer. Certain types of healthy cells also naturally need to cycle, such as bone marrow cells (which give rise to red blood cells, white blood cells, and platelets), hair follicle cells, skin cells, and cells lining the oral cavity and the gastrointestinal tract. As a result, chemotherapy targets and kills both cycling healthy cells and cycling cancer cells. This, in turn, leads to a spectrum of chemotherapy-induced side effects, from unpleasant to life-threatening.

ALRN-6924, an investigational first-in-class MDM2/MDMX dual inhibitor, is administered to cancer patients shortly before chemotherapy. ALRN-6924 is designed to selectively activate normal p53 protein in patients’ healthy cells, temporarily and reversibly pausing cell cycling to shield healthy cells from chemotherapy. The protection is limited to healthy cells, as ALRN-6924 cannot work in p53-mutated cancer cells given that p53 has lost function in those cells. Therefore, cancer cells continue to cycle uninterrupted, remaining fully susceptible to destruction by chemotherapy.

Entry into a Material Definitive Agreement

On August 3, 2020, Achieve Life Sciences, Inc. ("Achieve") reported that it entered into an underwriting agreement (the "Underwriting Agreement") with Lake Street Capital Markets, LLC (the "Underwriter"), pursuant to which Achieve agreed to issue and sell an aggregate of (a) 476,187 shares of its common stock (the "Shares") and (b) pre-funded warrants to purchase 142,857 shares of its common stock (the "Pre-Funded Warrants") to the Underwriters (the "Offering") (Filing, 8-K, OncoGenex Pharmaceuticals, AUG 3, 2020, View Source [SID1234562863]). The Shares will be sold at the public offering price of $10.50 per share. The Pre-Funded Warrants will be sold at a public offering price of $10.499 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $0.001 per share exercise price for each such Pre-Funded Warrant. Pursuant to the Underwriting Agreement, Achieve has also granted the Underwriters a 30-day option to purchase up to an additional 92,856 shares of its common stock. The Underwriting Agreement contains customary representations and warranties, conditions to closing, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The Offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-229019) that was filed by Achieve with the Securities and Exchange Commission ("SEC") on December 26, 2018, and declared effective by the SEC on February 11, 2019, and a related prospectus supplement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to Achieve.

Achieve estimates that net proceeds from the Offering will be approximately $5.9 million, after deducting underwriting discounts and commissions and estimated Offering expenses, and assuming no exercise of the Underwriters’ option to purchase additional shares. Achieve intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to fund clinical research and development, and for general working capital. Achieve expects the Offering to close on August 6, 2020, subject to the satisfaction of customary closing conditions.

The Underwriting Agreement is filed as Exhibit 1.1 to this report and the foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. The Pre-Funded Warrant is filed as Exhibit 4.1 to this report and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit. A copy of the opinion of Fenwick & West LLP, relating to the validity of the securities offered in connection with the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1.